Le Lézard
Subject: ATY

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of HemaCare Corporation


NEW YORK, Dec. 16, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by HemaCare Corporation (OTCMKTS: HEMA) and its board of directors concerning the proposed acquisition of the company by Charles River Laboratories International, Inc. (NYSE: CRL). Stockholders will receive $25.40 per share of HemaCare Corporation common stock that they hold. The transaction is valued at approximately $380 million and is expected to close in the first quarter of 2020.

If you are a stockholder of HemaCare Corporation and are interested in obtaining additional information regarding this investigation, please visit us at: http://www.rowleylawpllc.com/investigation/hema. You may also contact Shane Rowley, Esq. at Rowley Law PLLC, 50 Main Street Suite 1000, White Plains, NY 10606, by email at [email protected], or by telephone at 914-400-1920 or 844-400-4643 (toll-free).  

Rowley Law PLLC represents shareholders nationwide in class actions and derivative lawsuits in complex corporate litigation. For more information about the firm and its attorneys, please visit http://www.rowleylawpllc.com

Attorney Advertising. Prior results do not guarantee a similar outcome.

SOURCE Rowley Law PLLC



News published on and distributed by: